Insider transactions

Barry E Greene

CIK 1291963 · President and CEO · last filed 2026-06-23

Barry E Greene is a President and CEO who has filed 107 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for DYN, was dated Jun 23, 2026. Across all open-market trades the lifetime net is −$58.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $14.8M across reported positions. 62 SEC filings were submitted jointly with ALNYLAM PHARMACEUTICALS, INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$14.84M
Companies
6
Total Filings
107
Lifetime Open-Market Net
-$58.92M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

Filer Profile

Reported Address
C/O KARYOPHARM THERAPEUTICS INC.
85 WELLS AVENUE, 2ND FLOOR
NEWTON, MA 02459
Related Filers
ALNYLAM PHARMACEUTICALS, INC. — 62 joint filings, latest 2020-09-11
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
DYN Director — $15.10 — $0 1 2026-06-23
KPTI Director 16,415 $0.73 $12.0K $87.9K 16 2026-05-26
Sage Therapeutics, Inc. (SAGE) Delisted President and CEO 0 $8.68 $0 $2.02M 13 2025-07-31
Acorda Therapeutics, Inc. (ACOR) Delisted Director 83 $0.66 $55 -$290.2K 20 2021-06-04
ALNY President 68,588 $216.15 $14.83M -$60.74M 55 2020-09-11
Regulus Therapeutics Inc. (RGLS) Delisted Director 51,254 $8.16 $418.2K $0 2 2012-11-07

Recent Filings

107 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-23 DYN Grant (A) — $0 EDGAR
2026-05-26 KPTI Grant (A) +15,508 $0 EDGAR
2025-07-31 Sage Therapeutics, Inc. (SAGE) Delisted Mixed −100,169 $0 EDGAR
2025-05-29 KPTI Grant (A) — $0 EDGAR
2025-04-11 Sage Therapeutics, Inc. (SAGE) Delisted Mixed +15,102 -$33.6K EDGAR
2025-01-21 Sage Therapeutics, Inc. (SAGE) Delisted Grant (A) — $0 EDGAR
2024-08-07 Sage Therapeutics, Inc. (SAGE) Delisted Mixed +38,127 -$110.0K EDGAR
2024-05-30 KPTI Grant (A) — $0 EDGAR
2024-02-15 Sage Therapeutics, Inc. (SAGE) Delisted Grant (A) — $0 EDGAR
2023-08-08 Sage Therapeutics, Inc. (SAGE) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 107
Page 1 of 11
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.